/SVA.TO

SVA.TO Stock - Sernova Corp.

Q: What is the analyst price target for SVA.TO?

Analyst price target information is not currently available for SVA.TO.

Q: What is SVA.TO's market cap?

Market capitalization information is not currently available for SVA.TO.

Healthcare|Biotechnology|TSX

$0.14+3.85%

+$0.01 (+3.85%) • Dec 22

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $0.15

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for SVA.TO

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2021

FY2022

FY2023

FY2024

FY2025

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta0.75

52W High$0.26

52W Low$0.12

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	N/A	N/A	N/A	N/A	N/A
Gross Profit	$-342,591	N/A	$-445,551	$-439,998	$-267,204
Gross Margin	N/A	N/A	N/A	N/A	N/A
Operating Income	$-15,124,648	$-31,838,097	$-41,130,617	$-24,176,476	$-6,865,955
Net Income	$-15,743,466	$-32,192,135	$-38,997,520	$-24,538,538	$-7,023,907
Net Margin	N/A	N/A	N/A	N/A	N/A
EPS	$-0.05	$-0.10	$-0.13	$-0.09	$-0.03

Company Overview

Sernova Corp. operates as a clinical-stage regenerative medicine therapeutics company in Canada. The company focuses on the development and commercialization of regenerative medicine therapeutics, including its proprietary Cell Pouch and associated technologies consisting of therapeutic cells and local cellular immune protection. Its Cell Pouch is a medical device designed to create a vascularized tissue environment for the transplantation and engraftment of therapeutic cells, which then release proteins and/or hormones for the long-term treatment of various serious chronic diseases, such as diabetes, hemophilia, and thyroid disease. Sernova Corp. has a research collaboration with AgeX Therapeutics, Inc. to generate immune-protected therapeutic cells; and a research agreement with the University of Miami to advance the development of Cell Pouch cell therapy platform. The company was incorporated in 1998 and is headquartered in London, Canada.

Visit Website

Earnings History & Surprises

SVA.TO

Beat Rate

24%

Last 17 quarters

Avg Surprise

-17.4%

EPS vs Estimate

Beats / Misses

4/9

4 met exactly

Latest EPS

$-0.01

Q4 2025

EPS Surprise History

Q1 24

0.0%

$-0.03vs$-0.03

Q2 24

-12.5%

$-0.03vs$-0.03

Q3 24

-33.3%

$-0.02vs$-0.01

Q4 24

+50.0%

$-0.01vs$-0.02

Q1 25

+13.1%

$-0.02vs$-0.02

Q2 25

+50.0%

$-0.01vs$-0.02

Q3 25

0.0%

$-0.01vs$-0.01

Q4 25

+34.0%

$-0.01vs$-0.01

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q1 2026	Mar 2, 2026	—	—	—	—
Q4 2025	Dec 22, 2025	$-0.01	$-0.01	+34.0%	✓ BEAT
Q3 2025	Sep 16, 2025	$-0.01	$-0.01	0.0%	= MET
Q2 2025	Jun 12, 2025	$-0.02	$-0.01	+50.0%	✓ BEAT
Q1 2025	Mar 17, 2025	$-0.02	$-0.02	+13.1%	✓ BEAT
Q4 2024	Dec 23, 2024	$-0.02	$-0.01	+50.0%	✓ BEAT
Q3 2024	Sep 16, 2024	$-0.01	$-0.02	-33.3%	✗ MISS
Q2 2024	Jun 14, 2024	$-0.03	$-0.03	-12.5%	✗ MISS
Q1 2024	Mar 18, 2024	$-0.03	$-0.03	0.0%	= MET
Q1 2024	Jan 29, 2024	$-0.03	$-0.04	-60.0%	✗ MISS
Q3 2023	Sep 13, 2023	$-0.03	$-0.03	-20.0%	✗ MISS
Q2 2023	Jun 13, 2023	$-0.02	$-0.03	-50.0%	✗ MISS
Q1 2023	Mar 16, 2023	$-0.02	$-0.03	-50.0%	✗ MISS
Q4 2022	Oct 31, 2022	$-0.02	$-0.03	-17.1%	✗ MISS
Q3 2022	Sep 14, 2022	$-0.02	$-0.02	0.0%	= MET
Q2 2022	Jun 27, 2022	$-0.01	$-0.02	-100.0%	✗ MISS
Q1 2022	Mar 29, 2022	$-0.01	$-0.02	-100.0%	✗ MISS
Q1 2022	Feb 15, 2022	$-0.01	$-0.01	0.0%	= MET
Q3 2021	Sep 29, 2021	—	$-0.01	—	—
Q2 2021	Jun 25, 2021	—	$-0.01	—	—